Hexarelin Guide: Potency, Cardiac Effects, Safety and Status

Hexarelin, also called examorelin, is a synthetic six-amino-acid peptide that triggers growth hormone release by imitating the body’s hunger hormone, ghrelin. Its amino acid sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, and it belongs to the growth hormone-releasing peptide (GHRP) family alongside GHRP-2 and GHRP-6.

Hexarelin was developed by the Italian company Mediolanum Farmaceutici, with synthesis attributed to the chemist Romano Deghenghi, as a more stable and more potent modification of GHRP-6. On a per-microgram basis it is the strongest of the classical peptide secretagogues: laboratory comparisons place it at roughly ten times the growth hormone-releasing potency of GHRP-6 and two to three times that of GHRP-2. That potency, rather than any therapeutic approval, is the reason hexarelin became a fixture in the performance and anti-aging underground.

It is worth being precise about what hexarelin is not. It is not a steroid, it is not growth hormone itself, and it is not the same compound as the non-peptide drug MK-677 (ibutamoren), even though both end up activating the same ghrelin receptor. The broader picture of how all these compounds relate to one another sits on our growth hormone secretagogues hub.

Where hexarelin came from

Hexarelin emerged from the 1990s effort to turn the growth hormone-releasing peptides into usable medicines. Where the earliest peptides in the family were fragile and weak, Deghenghi’s team engineered hexarelin to resist breakdown and to act strongly enough to work by injection and, to a lesser degree, by nasal and oral routes. For a period it was a serious pharmaceutical candidate for growth hormone deficiency and for age-related frailty. Two things ended that path. The effect faded with repeated dosing, the tachyphylaxis problem covered further down, and recombinant growth hormone became widely available, removing much of the commercial reason to develop an indirect releaser. Hexarelin survived not as a licensed drug but as a research tool and a fixture of the performance underground.

The bottom line: Hexarelin is the most potent classical GHRP, a peptide ghrelin mimetic derived from GHRP-6 and never marketed as a medicine.

Hexarelin acts on two different receptors, and that dual action is what sets it apart from every other peptide in its class. One receptor drives growth hormone release; the other sits in heart tissue and produces effects that have nothing to do with growth hormone at all.

The ghrelin-receptor pathway

Hexarelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a) in the pituitary and hypothalamus, the same receptor activated by ghrelin and by other GHRPs. Activation prompts the pituitary’s somatotroph cells to release a pulse of growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1). The intracellular signal runs through a phospholipid-dependent protein kinase C pathway that is distinct from the pathway used by growth hormone-releasing hormone, which is why a GHRP and a GHRH analogue produce a larger combined pulse than either does alone.

The CD36 cardiac pathway

Hexarelin’s second target is CD36, a scavenger receptor found on heart muscle cells, macrophages and fat tissue. Through CD36 it activates pro-survival signalling cascades, including the PI3K/Akt and ERK1/2 pathways, that protect cardiomyocytes from death during oxygen starvation. Animal work has shown these cardiac effects persist even in growth hormone-deficient and pituitary-removed models, confirming that they are largely independent of growth hormone. No other GHRP engages this receptor in the same way, and it is the single most distinctive thing about hexarelin’s pharmacology.

This is why hexarelin was investigated as a potential heart drug and not only as a growth promoter. In preclinical models of heart attack and reperfusion injury, CD36 activation by hexarelin reduced the death of heart muscle cells and limited the size of the damaged area, and CD36 itself sits at the centre of how cardiac cells take up and burn fatty acids for fuel. The idea that came out of this work was that a CD36-active peptide might shield a stressed or failing heart through a route entirely separate from growth hormone. That mechanism is biologically real and is the reason hexarelin is pharmacologically interesting, but whether it ever produces a benefit a patient would actually notice is a separate question, taken up in the evidence section below.

The bottom line: Hexarelin works through the ghrelin receptor for growth hormone release and, uniquely, through the CD36 receptor for growth hormone-independent cardiac effects.

Hexarelin reliably raises growth hormone in humans, but its effect fades with continuous use, and its much-promoted cardiac benefits rest only on small, short studies from a single research group. The evidence is best read tier by tier rather than as one undifferentiated body of “research”.

Claim	Evidence tier	Where it comes from
Raises growth hormone	Human clinical	Dose-finding trials, all injection routes
Effect weakens over weeks	Human clinical	16-week desensitisation study
Short-term cardiac boost	Small acute human studies	Single-dose echocardiography work
Protects heart from ischemia	Animal (preclinical)	Rat and rabbit models
Builds muscle or burns fat	Not demonstrated	No controlled trials in athletes

Growth hormone release

The single most reproducible finding is that hexarelin causes a strong, fast pulse of growth hormone. In a 1994 study led by Ezio Ghigo and colleagues, hexarelin produced clear growth hormone responses after intravenous, subcutaneous, intranasal and even oral administration, with subcutaneous delivery far more effective than the nasal or oral routes. The peptide was tested in healthy adults and in short-statured children, and it advanced into Phase II clinical trials for growth hormone deficiency before development stalled. This is genuine human clinical evidence, not animal data or user anecdote.

The desensitisation problem

The reason hexarelin never became a chronic therapy is that the body adapts to it. In a 1998 study by Asad Rahim, P A O’Neill and Stephen Shalet, twelve healthy elderly volunteers received twice-daily subcutaneous hexarelin for 16 weeks. The area under the growth hormone curve fell from 19.1 at week zero to 13.1 at week one, 12.3 at week four and 10.5 at week sixteen, a statistically significant decline of roughly forty-five percent. The reassuring part is that the blunting was partial and reversible: four weeks after stopping, the response climbed back to 19.4, essentially baseline. The mechanism is thought to combine receptor internalisation, increased somatostatin tone and IGF-1 feedback.

Cardiac effects in humans

Hexarelin’s cardiac story is the most interesting and the most overstated. A series of small studies from a single Italian group in Turin (Bisi, Broglio, Ghigo and colleagues) between roughly 1999 and 2002 showed that a single intravenous dose acutely improved heart function. In healthy adults, hexarelin raised left ventricular ejection fraction from about 64 percent to 71 percent, an effect that appeared within 15 minutes, peaked at 30 and faded by 60. Critically, the same effect showed up in growth hormone-deficient patients whose growth hormone barely moved, confirming the CD36 pathway. The most striking experiment studied 24 coronary-artery-disease patients during bypass surgery: hexarelin promptly improved ejection fraction, cardiac index and cardiac output, while growth hormone, GHRH and placebo did nothing.

The honest caveat is just as important. Every one of those cardiac studies used a single dose, measured surrogate imaging endpoints rather than survival or heart attacks, enrolled small numbers, and came from essentially one research centre. No long-term randomised trial has ever tested whether hexarelin improves hard clinical outcomes, and the compound’s clinical development quietly ended more than two decades ago. The cardioprotection narrative is a promising hypothesis that was never carried over the line.

The bottom line: Hexarelin’s growth hormone release is well documented in humans, its effect attenuates within weeks of daily use, and its cardiac benefits remain confined to small acute studies with no long-term outcome data.

Hexarelin is not an approved drug in any country, and it is banned in elite sport worldwide. Its legal position varies in the detail from market to market, but nowhere is there a licensed hexarelin product a patient could be prescribed.

Jurisdiction	Status
United States (FDA)	Not approved; not on the 503A compounding bulks list
United Kingdom (MHRA)	Unlicensed medicine; not approved for human use
Australia (TGA)	Schedule 4 prescription-only; no registered product
Sport (WADA)	Prohibited at all times under section S2

In sport, the World Anti-Doping Agency lists examorelin (hexarelin) by name among the growth hormone-releasing peptides in section S2, prohibited both in and out of competition for every athlete bound by the Code. In the United States the relevant question for most clinics is whether hexarelin can be compounded, and the answer is no: it does not appear on the FDA’s 503A bulks list, and how that compounding framework works is explained in our guide to FDA Category 1 versus Category 2. The wider legal position in each market is set out in our guides to peptide legality in the US, UK and Australia.

It is worth being clear about what that sporting ban means in practice. The World Anti-Doping Agency classifies examorelin as a Specified Substance, a label that can allow a more flexible penalty when an athlete proves the use was not intended to boost performance, but the compound stays fully prohibited and a positive test is still a violation. Accredited laboratories screen for the peptide and its metabolites in athlete samples, and because hexarelin leaves the body quickly the short detection window was historically part of its appeal. The Specified-Substance category is about how a case is judged, not about making hexarelin in any sense allowed.

The bottom line: No country has ever approved a hexarelin product, and the peptide is a banned substance in all WADA-governed sport.

Hexarelin raises cortisol, ACTH and prolactin more than the selective peptides do, and its long-term safety in healthy people has never been established. It is a potent growth hormone releaser, not a clean one.

Like other GHRPs, hexarelin does not confine its action to growth hormone. It stimulates the release of ACTH and the resulting rise in cortisol, and it elevates prolactin. This off-target hormonal activity is more pronounced than with the cleaner pentapeptide ipamorelin, which is one reason ipamorelin is often preferred where receptor selectivity matters. The desensitisation discussed above is itself a safety-relevant property, because it means the dose escalation people are tempted into can push the cortisol and prolactin effects without restoring the growth hormone effect.

Beyond the compound’s own pharmacology, there is the problem of the supply chain. Hexarelin sold outside a regulated medicine pathway carries no guarantee of identity, purity or sterility, and the controlled human studies above used pharmaceutical-grade peptide that bears little resemblance to a research-chemical vial. Anyone evaluating a product should understand what a genuine third-party analysis does and does not prove, which we cover in our guide on how to read a certificate of analysis.

The bottom line: Hexarelin’s main documented drawbacks are elevated cortisol, ACTH and prolactin plus loss of effect over time, and its long-term safety profile is simply unknown.

Hexarelin is more potent than GHRP-2 and GHRP-6 but less selective than ipamorelin, and unlike all of them it also acts on the heart. Each related compound has its own full profile.

• GHRP-2 (pralmorelin) is the second most potent classical GHRP and the only growth hormone secretagogue ever approved by a national regulator, as a diagnostic agent in Japan.
• GHRP-6 is the original scaffold from which hexarelin was derived, best known for its strong appetite-stimulating effect.
• Ipamorelin is the selective pentapeptide that releases growth hormone with minimal cortisol or prolactin, the opposite design philosophy to hexarelin.
• CJC-1295 is a GHRH analogue rather than a GHRP, often discussed alongside ghrelin-receptor peptides because the two classes produce a larger combined growth hormone pulse.

The bottom line: Among growth hormone secretagogues hexarelin is the potency leader and the only cardiac-active member, but it trades selectivity and durability for that potency.

Is hexarelin legal?

Hexarelin is not an approved medicine in the US, UK or Australia, where it is an unapproved or prescription-only substance, and it is banned in all WADA-governed sport.

Is hexarelin a steroid?

No. Hexarelin is a peptide growth hormone secretagogue that stimulates the pituitary to release growth hormone; it is not an anabolic steroid and works by a completely different mechanism.

What makes hexarelin different from other GHRPs?

Hexarelin is the most potent classical GHRP and the only one that also activates the CD36 receptor in heart tissue, producing growth hormone-independent cardiac effects no other GHRP shares.

Does hexarelin build muscle or burn fat?

No controlled trial has tested hexarelin for muscle gain or fat loss in athletes or healthy adults; claims about body composition rest on anecdote and on the assumed downstream effects of raised growth hormone.

Why does hexarelin stop working?

Daily hexarelin causes the ghrelin receptor to down-regulate, and a 16-week human study found the growth hormone response fell by about forty-five percent, recovering only after the peptide was stopped.

Is hexarelin the same as GHRP-6?

No. Hexarelin is a chemically modified, more stable and far more potent descendant of GHRP-6, not the same molecule; the structural change that created it makes hexarelin release growth hormone much more strongly for a given dose.

How is hexarelin detected in anti-doping tests?

Because it is a prohibited peptide, accredited laboratories screen athlete blood and urine for hexarelin and its metabolites, and any positive finding is treated as an anti-doping rule violation.